PF-Atlas › Weekly Digest › 2026-W39

Week of Sept 15–22, 2026: A New Breathing-Test Trial Opens, PDE4 Inhibitors in the Spotlight

2026-09-15 → 2026-09-22 · Active week

The week in plain words

This week one new clinical trial began recruiting — it studies how well IPF patients can breathe in through inhalers, which matters for inhaled drug delivery. Twelve new research papers appeared, covering drug side effects, diagnosis delays, and a promising way to group patients by their lung fluid chemistry. No cure exists; approved treatments can only slow the scarring, not reverse it.

Where things stand now

IPF still has no cure and no way to undo existing lung scarring. The two longest-standing approved drugs — pirfenidone and nintedanib — slow the disease. A newer FDA-approved option, Nerandomilast (Jascayd), approved October 2025, targets a specific inflammation-controlling enzyme called PDE4B. Inhaled Treprostinil and Admilparant are in late-stage (Phase III) trials with positive signals but are not yet fully approved for IPF. Everything else in the pipeline — including experimental approaches aimed at regenerating lung tissue — is still investigational, meaning it has not been proven safe and effective enough for routine use.

The best option right now

For patients diagnosed today, the most current clinically established options are Nerandomilast/Jascayd (FDA-approved Oct 2025), alongside the longer-standing approved drugs pirfenidone and nintedanib. All three slow lung-function decline — none reverses or heals scarring. A new paper this week (Yang X et al., 2026) compared the real-world side-effect profiles of pirfenidone and nintedanib, finding differences in gut and skin reactions — a useful reminder that choosing between them often comes down to which side effects a patient can better tolerate. Inhaled Treprostinil and Admilparant are promising Phase III options but are not yet standard-of-care. Any treatment decision must be made with a specialist.

How close are we to regeneration

Lung regeneration in IPF remains a research goal, not an available treatment. The three experimental approaches tracked here are all pre-human or very early stage: uPAR-CAR-T (engineered immune cells that clear out 'zombie' senescent cells) is preclinical lab work; the Senolytics + WNT Agonist combination (a two-step approach to clear damaged cells then stimulate healthy ones) is still a concept being tested in animals; and an AI Knowledge Graph is helping scientists connect ideas across fields faster. None of these is available to patients. No new regeneration data arrived this week.

Study of the week

The editors flagged a study by Kurasawa, Tanaka, Miyao and colleagues (Respiratory Investigation, 2026) as this week's standout. Researchers collected fluid from deep in patients' lungs — a procedure called bronchoalveolar lavage, basically a careful lung rinse — and measured dozens of small signaling proteins called cytokines. Using those measurements, they grouped patients into distinct biological 'phenotypes' (think of it like sorting people by blood type, but for lung inflammation patterns). Crucially, these groups predicted how patients' disease progressed differently over time. Why does this matter? If doctors can identify which 'inflammation fingerprint' a patient has at diagnosis, they may eventually be able to match that patient to the treatment most likely to help them — a step toward personalized IPF care. This is still research, not yet a clinical tool.

What changed since last week

One change from last week: a brand-new trial (NCT07820254) opened recruitment. It focuses on inspiratory flow rate — how forcefully and quickly IPF patients can inhale — which is important because many inhaled medications require a minimum breath strength to work properly. No trials changed status this week. The overall treatment landscape is unchanged: no new approvals, no trial completions, no safety alerts appeared in this week's data.

Sources this week

New / updated trials
New studies
All weekly digests
Medical disclaimer. This digest summarizes public clinical-trial and research data in plain language for information only. It is not medical advice, a treatment recommendation, or a promise of any outcome. Evidence changes; treatments described as investigational are not proven cures. Always verify with ClinicalTrials.gov, PubMed and a qualified pulmonologist before any decision.